The aim of this study was to investigate the possible association between the functional polymorphism in the upstream regulatory region of the serotonin transporter gene (5-HTTLPR) and the prophylactic efficacy of lithium in mood disorders. Two hundred and one subjects affected by bipolar (n = 167) and major depressive (n = 34) disorder were followed prospectively for an average of 58.2 months and were typed for their 5-HTTLPR variant using polymerase chain reaction techniques. 5-HTTLPR variants were associated with lithium outcome (F = 5.35; df = 2,198; P = 0.005). Subjects with the s/s variant showed a worse response compared to both l/s and l/l variants. Consideration of possible stratification effects such as sex, polarity, age at onset, duration of lithium treatment and previous episodes did not influence the observed association. 5-HTTLPR variants may be a possible influencing factor for the prophylactic efficacy of lithium in mood disorders. The Pharmacogenomics Journal (2001) 1, 71-77.
INTRODUCTION
Lithium is an effective prophylactic agent in mood disorders but not all patients equally respond to lithium therapy. Clinical predictors account for less than half of the variance [1] [2] [3] [4] [5] [6] [7] [8] and there is evidence suggesting that genetic factors play a substantial role. A positive family history of bipolar illness has repeatedly been associated with better outcome, [9] [10] [11] and lithium responder probands proved to have a higher genetic loading when compared to non-responders. [12] [13] [14] In light of this evidence, lithium response has been used as a tool to select homogeneous samples for association studies with genetic markers. 15, 16 Possible genetic predictors of lithium response have not, however, yet been evaluated.
The mode of action of lithium salts used in the prophylaxis of affective disorders is still unknown. Lithium activity may be mediated by second-messenger and nonspecific ionic flux effects. 17 But a number of other complementary mechanisms have been proposed. 18 Disturbances of the serotoninergic neurotransmitter system have been implicated in the pathogenesis of mood disorders 19, 20 and serotonin (5-HT) has also been repeatedly implicated in the mechanism of action of lithium. Animal studies evidenced that short and longterm lithium treatment enhanced 5-HT efflux in rat hippocampus [21] [22] [23] and in the lateral hypothalamus. 24 Chronic lithium administration enhances both electrophysiological and behavioral responses mediated by postsynaptic 5-HT1A receptors, 25 with a significant reduction of 5-HT1 binding sites in the hippocampus. 26 Moreover, the chronic administration of lithium increased the number of 5-HT transporters in cortical regions. 27, 28 Further evidence supports the view that lithium treatment acts through an enhancement of 5-HT function: lithium salts induced significant increases in plasma-free 5HT, 29 and the prolactin response to tryptophan was significantly enhanced after short-term lithium treatment. 30 The turnover of 5-HT in either frontal cortex or hippocampus was facilitated by lithium and lithium treatment causes the down-regulation of postsynaptic 5-HT1 and 5-HT2 receptors. 31 However, this view is not unequivocally accepted because others have suggested that the effects of lithium on synaptic transmission and on neuronal excitability appeared independent from changes in endogenous 5-HT. [32] [33] [34] [35] Taken together, the previous studies show the effect of lithium on 5-HT function at the levels of precursor uptake, synthesis, storage, catabolism, release, receptors, and receptor-effector interactions. The weight of this evidence suggests that lithium primary actions on 5-HT may be presynaptic, with many secondary postsynaptic effects. Finally, studies in humans generally suggest that lithium has a net enhancing effect on 5-HT function. 18 These actions of lithium may serve to correct 5-HT function abnormalities involved in the pathogenesis of mood disorders. 36 The serotonin transporter is the major determinant of serotonin inactivation following release at synapses and it is the site of action of most antidepressants. The gene coding for it has been proposed as a possible candidate for involvement in the pathogenesis of major psychoses. A functional polymorphism in the upstream regulatory region of the gene has been associated with both major depressive and bipolar disorders, [37] [38] [39] although subsequent studies did not replicate these results. [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] The gene also proved to be associated or showed conflicting evidence with a number of other conditions, like anxiety-related traits in controls [53] [54] [55] [56] [57] [58] [59] and in depressed patients, 60 seasonal affective disorder, 49, 61 anxiety disorders, 62 autism, [63] [64] [65] [66] [67] severe alcoholism, 68, 69 suicidal behavior, [70] [71] [72] [73] psychotic symptomatology in neuroleptic-free schizophrenics, 74 with schizophrenia [75] [76] [77] [78] [79] [80] but not with major psychoses symptomatology. 81, 82 The polymorphism in the upstream is a deletion/insertion (5-HTTLPR) located exactly at the 5′-flanking regulatory region of the serotonin transporter gene on chromosome 17q11.2. It consists of a 44-bp insertion or deletion involving repeat elements 6-8 (from bp −1212 to bp −1255). 53 Heils 83 found that in vitro the basal activity of the long (l) variant was more than twice that of the short (s) form of the 5-HTTLPR, suggesting that serotonin transporter gene transcription is modulated by variants of the 5-HTTLPR with the s allele corresponding to low serotonin uptake activity. The above mentioned evidence suggests that 5-HTTLPR is a potential candidate as a prediction of lithium response in mood disorders. We have therefore hypothesized that 5-HTTLPR variants could be involved in individual susceptibility to lithium prophylactic efficacy in mood disorders.
RESULTS
Of the 201 patients, 53 (26.4%) had no DSM-IV mood disorder episodes during follow up and 88 (43.8%) had a decrease in episode frequency, the remaining 60 (29.8%) had an increased episode frequency. The whole sample showed a significant reduction in episode frequency after lithium treatment (pre-lithium treatment recurrence index vs on-lithium treatment recurrence index: 8.35 vs 4.25;
The Pharmacogenomics Journal t = 5.63; df = 200, P Ͻ 0.0001). 5-HTTLPR genotypes were in Hardy-Weinberg equilibrium ( 2 = 0.01, df = 1, P = 0.91). Table 1 shows the sample divided according to 5-HTTLPR variants. Clinical and demographic variables were not significantly different among 5-HTTLPR variants except for a lower recurrency index for s/s subjects. Table 2 shows that 5-HTTLPR genotypes were associated with lithium efficacy as measured by the pre vs on lithium treatment recurrence index. In particular subjects with the s/s genotype were less responsive to lithium when compared to s/l subjects (P = 0.009). Consideration of possible stratification effects using ANCOVA such as sex, polarity, age at onset, duration of lithium treatment or pre-lithium episodes did not influence the observed association (P Ͻ 0.006 for all comparisons). We then separated depressive and manic episodes. Detailed information was available for 63 subjects. In this subsample no significant differences were observed for both manic (P = 0.24) and depressive episodes (P = 0.43).
DISCUSSION
Homozygosity for the short variant of the functional polymorphism in the upstream regulatory region of the serotonin transporter gene showed a worse lithium outcome in our sample of mood disorder subjects. This was also true when known clinical and demographic risk factors, such as sex, polarity, onset, and duration of lithium administration were controlled for. To our knowledge, genetic liability factors for lithium response have not yet been studied except for our preliminary investigation of dopaminergic markers in the context of the BIOMED I project. 84 In that analysis we evidenced a marginal association of the dopamine receptor D2 variants with lithium response. Our center is currently testing a number of possible candidate genes within both the dopaminergic and serotoninergic systems. We have recently reported that the A218C gene variant on the tryptophan hydroxylase gene was marginally associated with lithium efficacy 85 and we excluded associations with other polymorphisms. [86] [87] [88] Recently, the 5-HTTLPR polymorphism has been also associated with the antidepressant response to certain selective serotonin reuptake inhibitors, such as fluvoxamine 89, 90 and paroxetine. 91, 92 A possible common mechanism may therefore underlie SSRI and lithium efficacy even if the exact mechanism of action of lithium activity is largely unknown. Converging evidence suggests a focus on the second-messenger system, but also aminergic systems, like the serotoninergic one, could be implicated. 36 It has been shown that the second-messenger mediated lithium activity depends on the activity of the first-messenger system: lithium activity is increased when first-messengers are hyperactive, while in normal conditions its activity is lower. 18 This view is consistent with the clinical effectiveness of lithium in mood disturbances and with the lack of any detectable effect in controls. 1 We may therefore provisionally hypothesize that the prophylactic efficacy of lithium may be regulated by the overall activity of the serotoninergic system, that is, in turn, influenced by 5-HTTLPR and TPH variants.
In the present study we observed that the 5-HTTLPR s/s variant differed both from s/l and l/l. This suggests more a Groups were homogeneously distributed among 5-HTTLPR variants except for a lower frequency of episodes for s/s subjects. Both raw and weighted measurements of lithium prophylactic efficacy are displayed. Subjected with the l/s and l/l variants have a higher reduction of recurrences while on lithium treatment compared to s/s subjects. Possible stratification biases have been tested through ANCOVA, however for displaying purposes data about polarity have been reported in the last line.
recessive than a codominant effect; both the initial report and some authors suggested a dominant effect of the s allele, 53,92-94 but others suggested a recessive effect. 47, 89, 91, 95 Conclusive findings are still lacking and will be achieved with larger samples and/or further basic and animal studies. In our sample, 5-HTTLPR l and s allele frequencies were respectively 0.57 and 0.43, they are similar to those of previously published samples in Caucasians. 39, 53, 61, 96 On the other hand, Asian frequencies were different from all Caucasian samples. 62, 97 Genetic studies may be limited by sampling biases and by power issues. Ethnic origin is frequently a cause of stratification bias but our sample was composed of subjects with Italian antecedents for at least two generations and Italy is characterized by a substantial genetic homogeneity. 98 It has been argued that most studies, like the present one, may be biased because the selection criteria limit the extent to which the sample is representative. 99 Subjects for the present study were recruited in a specialized center and a bias toward a higher severity of mood disorder has been observed, with a lower DSM-IV Axis I comorbidity.
100,101 But www.nature.com/tpj the purpose of this study was to enucleate predictive factors and this is more likely when confounding variables, like Axis I comorbidity or substance abuse, are minimized. The power of our sample was enough to detect a standardized difference (effect size) up to d = 0.45 (depending on the frequency of the risk genotype, considering a power of 0.8 and alpha Ͻ0.05 two-tailed), that corresponds to a difference of 4.7 points on the lithium efficacy index. The difference in our sample was 5.37 points, therefore it is within the range of detectable differences. However, we may not rule out the possibility of a false positive finding. In terms of explained variance, 5-HTTLPR variants accounted for 4.8% of the whole variance (considering the values of Table 2 , f = 0.226), 102 this is in accordance with the current view of polygenic inheritance of complex traits. 103, 104 A limitation of the present study is that a number of clinical variables were not considered, such as number of days of hospitalization, the episodes' sequence type (depression/mania), 4 subthreshold symptomatology, 105 life events or the time course of plasma lithium levels. With regard to this last point, lithium levels were maintained within range values in our setting and, though high-range serum levels have been associated with better outcome, there have been doubts raised as to their relevance. 106, 107 Lithium has been at times described as more effective with manic episodes, we were not able to test this issue, however an equal efficacy with manic and depressive episodes was frequently reported. [108] [109] [110] Finally, while a very large number of variables intervene in modifying the time course of mood disorders, and of psychiatric disturbances in general, all variables could never be completely controlled.
1 Replication using independent samples is therefore required.
MATERIALS AND METHODS

Sample
Two hundred and one subjects consecutively admitted to the Lithium Clinic for Mood Disorders of S. Raffaele Hospital in Milan were included in this study (Table 1) . Patients considered for this study were part of the sample collected in the context of the European Collaborative Project on Affective Disorders, 84, 111 124 subjects have been included in previous analysis with other polymorphisms. [85] [86] [87] [88] All patients were evaluated using the Schedule for Affective Disorders and Schizophrenia (SADS), 112 and/or the Operational Criteria for Psychotic Illness checklist (OPCRIT). 113 Lifetime diagnoses were assigned by two independent psychiatrists on the basis of interviews and medical records, according to DSM-IV criteria. 114 Information about the illness before contact with our center was collected following the best estimate procedure, interviewing the subjects, family members, previous health professionals and obtaining records when possible. 115 The presence of concomitant diagnoses of mental retardation, drug dependence, or other Axis I disorders, together with somatic or neurological illnesses that impaired psychiatric evaluation (eg hypothyroidism mimicking a depressive state) represented exclusion criteria as well as medication non-compliance as detected by persistently low lithium plasma levels. This allowed only a small part of our subjects to be included in the study. All enrolled patients received lithium as maintenance therapy with doses adjusted to obtain 12-h plasma levels within the standard therapeutic range. The mean values ranged between 0.4 and 0.7 mEq l −1 for plasma levels and between 0.2 and 0.4 mEq l −1 for red blood cell levels. Determination of lithium levels in each patient was performed every 3 months and, at the same time, the clinical condition of patients was evaluated using the Hamilton Rating Scale for Depression (21-HAMD), 116 and Manic Rating Scale for Mania. 117 Patients were evaluated weekly, or more often, during active phases of the illness and every 4 months during euthymia. If patients presented a major depressive (HAMD Ͼ18) or a manic (Young rating scale Ͼ20) episode after a euthymic period of at least 6 months, they were recognized as having a new recurrence 118 and received additional care (hospitalization when needed) and treatment according to the judgment of their clinician. Subclinical episodes such as minor depressive episodes were not defined as new recurrences. All patients received our standard clinical management intervention, involving an explanation about the ill-
The Pharmacogenomics Journal ness, lithium therapy to the patient and his/her relatives, and monitoring of the course of the illness. 119 No formal cognitive, behavioral or other psychotherapy was administered. Informed consent was obtained from all probands after the procedure had been fully explained; probands were unrelated and of Italian descent with antecedents from all parts of the country. The study was carried out in accordance with the principles of the Declaration of Helsinki. 120 Efficacy of lithium treatment is difficult to establish. 1 The more straightforward method is to evaluate a complete absence of illness episodes after lithium treatment. But this happens only in a limited number of subjects, and the majority experience a decrease in number of illness episodes or in their severity. 1 However, the raw number of episodes is dependent from the time of follow-up, and, on the other hand, measures weighted on the time of follow-up may vary considerably for very short observations. Therefore we reported both raw and weighted measurements and we excluded cases followed for less than 18 months. The recurrence rates before and during prophylaxis were evaluated by considering the occurring episodes of illness over the months from the onset to the beginning of lithium prophylaxis (pre-lithium treatment recurrence index = number of episodes/month duration of illness before lithium treatment × 100) and the occurring episodes from the beginning of prophylaxis to the moment of assessment (on-lithium treatment recurrence index = number of recurrences/month duration of lithium treatment × 100). The efficacy of prophylactic treatment was evaluated by calculating the difference between the pre-lithium treatment recurrence index and the on-lithium treatment recurrence index.
121,122
DNA Analysis
Genomic DNA was extracted from leukocytes by NaCl precipitation. 123 PCR forward primer 5′-GGCGTTGCCGCT CTGAATGC-3′ and reverse primer 5′-GAGGGACTGAGC TGGACAACCAC-3′ were employed. Thirty-five cycles of 1 min at 95°C, 1 min at 61°C and 1 min at 72°C were performed. The assay mix contained in a volume of 30 l 50 ng genomic DNA, 2.5 mM dNTPs, 0.1 g of sense and antisense primer, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 5% DMSO and 1 U Taq Polymerase. PCR products were separated on 3% agarose gels supplemented with ethidium bromide allowing differentiation of the long (528 bp) and the short (484 bp) variant.
Statistical Analysis
The difference between the pre-treatment index and the ongoing-lithium treatment index (as defined in the Methods section) was used as the dependent variable, testing possible differences among TPH variants. Differences were assessed using Analysis of Variance (ANOVA) and posthoc Newmann-Keuls tests. Analysis of Covariance (ANCOVA) was used to include possible confounders. Alpha levels were considered significant when less than 0.05. The power of our sample to detect differences amongst 5-HTTLPR variants was calculated considering an alpha value of 5% two-tailed. With these parameters in our sample we had a high power (0.80) to detect a medium effect size (d = 0.45, f = 0.22) that corresponded to a difference of approximately 4.7 points between the two major genotypes on the difference between pre-treatment index and the ongoing-lithium treatment index.
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